EFFICACY EVALUATION OF A MONOCLONAL ANTIBODY AGAINST THE EPIDERMAL GROWTH FACTORS RECEPTOR IN THE MODEL OF SUBCUTANEOUS XENOGRAFT IN IMMUNODEFICIENT MICE
This article presents the results of the comparative antitumor efficacy study of two test articles of therapeutic humanized monoclonal antibodies against epidermal growth factor receptor (EGFR) manufactured by Russian biopharmaceutical company CJSC “Biocad” and the commercial drug “Erbitux®” (Merck,...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2016-02-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/222 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850030624228769792 |
|---|---|
| author | Ya. Yu. Ustyugov A. A. Aleksandrov M. V. Artyukova M. A. Varavko |
| author_facet | Ya. Yu. Ustyugov A. A. Aleksandrov M. V. Artyukova M. A. Varavko |
| author_sort | Ya. Yu. Ustyugov |
| collection | DOAJ |
| description | This article presents the results of the comparative antitumor efficacy study of two test articles of therapeutic humanized monoclonal antibodies against epidermal growth factor receptor (EGFR) manufactured by Russian biopharmaceutical company CJSC “Biocad” and the commercial drug “Erbitux®” (Merck, Germany) in subcutaneous xenografts model using human epidermoid carcinoma A431NS cell line. EGFR overexpression in epithelial tumor cells is a commonly known fact that determines use of this receptor as a target for therapeutic monoclonal antibodies. The basic mechanism of action of such drugs is blocking of epithelial cells proliferation through competitive binding to EGFR. Evaluation of tumor growth dynamics in immunodeficient (Nu/Nu) mice was performed during in vivo experiment using two parameters: tumor growth index and tumor growth inhibition (TGI, %). The results received with used study design show that antitumor effects of the test articles manufactured by CJSC “Biocad” and the commercial comparator drug “Erbitux®” estimated by values of TGI and tumor growth index are comparable. |
| format | Article |
| id | doaj-art-02952973f04f468c9c83fbc3a4c6d2d2 |
| institution | DOAJ |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| publishDate | 2016-02-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj-art-02952973f04f468c9c83fbc3a4c6d2d22025-08-20T02:59:11ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682016-02-01145157222EFFICACY EVALUATION OF A MONOCLONAL ANTIBODY AGAINST THE EPIDERMAL GROWTH FACTORS RECEPTOR IN THE MODEL OF SUBCUTANEOUS XENOGRAFT IN IMMUNODEFICIENT MICEYa. Yu. Ustyugov0A. A. Aleksandrov1M. V. Artyukova2M. A. Varavko3Biocad JSC, Moscow Region, LyubuchanyBiocad JSC, Moscow Region, LyubuchanyBiocad JSC, Moscow Region, LyubuchanyBiocad JSC, Moscow Region, LyubuchanyThis article presents the results of the comparative antitumor efficacy study of two test articles of therapeutic humanized monoclonal antibodies against epidermal growth factor receptor (EGFR) manufactured by Russian biopharmaceutical company CJSC “Biocad” and the commercial drug “Erbitux®” (Merck, Germany) in subcutaneous xenografts model using human epidermoid carcinoma A431NS cell line. EGFR overexpression in epithelial tumor cells is a commonly known fact that determines use of this receptor as a target for therapeutic monoclonal antibodies. The basic mechanism of action of such drugs is blocking of epithelial cells proliferation through competitive binding to EGFR. Evaluation of tumor growth dynamics in immunodeficient (Nu/Nu) mice was performed during in vivo experiment using two parameters: tumor growth index and tumor growth inhibition (TGI, %). The results received with used study design show that antitumor effects of the test articles manufactured by CJSC “Biocad” and the commercial comparator drug “Erbitux®” estimated by values of TGI and tumor growth index are comparable.https://www.siboncoj.ru/jour/article/view/222a431ns, erbitux®, xenograft, immunodeficient mice, tumor growth inhibition, antitumor efficacy, human epidermoid carcinoma, tumor growth index |
| spellingShingle | Ya. Yu. Ustyugov A. A. Aleksandrov M. V. Artyukova M. A. Varavko EFFICACY EVALUATION OF A MONOCLONAL ANTIBODY AGAINST THE EPIDERMAL GROWTH FACTORS RECEPTOR IN THE MODEL OF SUBCUTANEOUS XENOGRAFT IN IMMUNODEFICIENT MICE Сибирский онкологический журнал a431ns, erbitux®, xenograft, immunodeficient mice, tumor growth inhibition, antitumor efficacy, human epidermoid carcinoma, tumor growth index |
| title | EFFICACY EVALUATION OF A MONOCLONAL ANTIBODY AGAINST THE EPIDERMAL GROWTH FACTORS RECEPTOR IN THE MODEL OF SUBCUTANEOUS XENOGRAFT IN IMMUNODEFICIENT MICE |
| title_full | EFFICACY EVALUATION OF A MONOCLONAL ANTIBODY AGAINST THE EPIDERMAL GROWTH FACTORS RECEPTOR IN THE MODEL OF SUBCUTANEOUS XENOGRAFT IN IMMUNODEFICIENT MICE |
| title_fullStr | EFFICACY EVALUATION OF A MONOCLONAL ANTIBODY AGAINST THE EPIDERMAL GROWTH FACTORS RECEPTOR IN THE MODEL OF SUBCUTANEOUS XENOGRAFT IN IMMUNODEFICIENT MICE |
| title_full_unstemmed | EFFICACY EVALUATION OF A MONOCLONAL ANTIBODY AGAINST THE EPIDERMAL GROWTH FACTORS RECEPTOR IN THE MODEL OF SUBCUTANEOUS XENOGRAFT IN IMMUNODEFICIENT MICE |
| title_short | EFFICACY EVALUATION OF A MONOCLONAL ANTIBODY AGAINST THE EPIDERMAL GROWTH FACTORS RECEPTOR IN THE MODEL OF SUBCUTANEOUS XENOGRAFT IN IMMUNODEFICIENT MICE |
| title_sort | efficacy evaluation of a monoclonal antibody against the epidermal growth factors receptor in the model of subcutaneous xenograft in immunodeficient mice |
| topic | a431ns, erbitux®, xenograft, immunodeficient mice, tumor growth inhibition, antitumor efficacy, human epidermoid carcinoma, tumor growth index |
| url | https://www.siboncoj.ru/jour/article/view/222 |
| work_keys_str_mv | AT yayuustyugov efficacyevaluationofamonoclonalantibodyagainsttheepidermalgrowthfactorsreceptorinthemodelofsubcutaneousxenograftinimmunodeficientmice AT aaaleksandrov efficacyevaluationofamonoclonalantibodyagainsttheepidermalgrowthfactorsreceptorinthemodelofsubcutaneousxenograftinimmunodeficientmice AT mvartyukova efficacyevaluationofamonoclonalantibodyagainsttheepidermalgrowthfactorsreceptorinthemodelofsubcutaneousxenograftinimmunodeficientmice AT mavaravko efficacyevaluationofamonoclonalantibodyagainsttheepidermalgrowthfactorsreceptorinthemodelofsubcutaneousxenograftinimmunodeficientmice |